Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration-Reference-Cited by-同舟云学术

Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration

Published:2019-04-26 Issue:1 Volume:23 Page:
ISSN:1364-8535
Container-title:Critical Care
language:en
Short-container-title:Crit Care

Author:

Aguilar Gerardo^ORCID,Ferriols Rafael,Martínez-Castro Sara,Ezquer Carlos,Pastor Ernesto,Carbonell José A.,Alós Manuel,Navarro David

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13054-019-2434-5.pdf

Reference5 articles.

1. Montravers P, Bassetti M. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. Curr Opin Infect Dis. 2018;31(6):587–e93.

2. Oliver WD, Heil EL, Gonzales JP, Mehrotra S, Robinett K, Saleeb P, Nicolau DP. Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;60(3):1899–901.

3. Kuti JL, Ghazi IM, Quintiliani R Jr, Shore E, Nicolau DP. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016;48:342–3.

4. Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy. 2016;36:e30–e3.

5. Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience. Int J Antimicrob Agents. 2018; [Epub ahead of print].

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam;Antimicrobial Agents and Chemotherapy;2024-09-04

2. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

3. Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese;Open Forum Infectious Diseases;2023-08-28

4. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients;Annals of Intensive Care;2023-07-18

5. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation;Journal of Clinical Medicine;2022-11-22